Key considerations for community physicians in the management of secondary AML

Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the complexities of secondary acute myeloid leukemia (AML), distinguishing between therapy-related AML and AML transforming from other malignancies. She emphasizes the importance of understanding prior treatments, such as hypomethylating agents, and highlights current therapies like CPX-351 and venetoclax. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.